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With increasingly large immunocompromised populations around the world,
opportunistic fungal pathogens such as Cryptococcus neoformans are a growing
cause of morbidity and mortality. To combat the paucity of antifungal
compounds, new drug targets must be investigated. Adenylosuccinate
synthetase is a crucial enzyme in the ATP de novo biosynthetic pathway,
catalyzing the formation of adenylosuccinate from inosine monophosphate
and aspartate. Although the enzyme is ubiquitous and well characterized in
other kingdoms, no crystallographic studies on the fungal protein have been
performed. Presented here are the expression, purification, crystallization and
initial crystallographic analyses of cryptococcal adenylosuccinate synthetase.
The crystals had the symmetry of space group P212121 and diffracted to 2.2 A˚
resolution.
1. Introduction
With the rise of the HIV/AIDS pandemic and the increased use of
immunosuppressive drugs in chemotherapy and organ transplanta-
tion, populations of individuals with defective immune systems are
higher than ever before. With such a large immunocompromised
population, opportunistic infections are a growing cause of morbidity
and mortality. Among these opportunists is the fungus Cryptococcus
neoformans, one of the foremost AIDS-defining illnesses. Infection
by this basidiomycete yeast begins with the inhalation of spores or
desiccated yeast cells (Idnurm et al., 2005). Individuals with healthy
immune systems generally clear infection by C. neoformans.
However, in immunocompromised individuals the fungus can
disseminate to the central nervous system to cause cryptococcal
meningoencephalitis, which is fatal if untreated (Idnurm et al., 2005).
Fungal infections are difficult to treat owing to the similarities of
their eukaryotic physiology to that of humans; the limited antifungal
agents available tend to target the few differences between the two
systems (Odds et al., 2003). Azoles (such as fluconazole) and polyene
compounds (such as amphotericin B) target ergosterol by inhibiting
the enzyme involved in its biosynthesis (lanosterol 14 -demethylase)
or by binding to ergosterol itself, respectively. New agents of this class
are frequently reported; however, few see active clinical development
(Ostrosky-Zeichner et al., 2010). Sordarins, which inhibit protein
synthesis via elongation factor 2 (Domı´nguez & Martı´n, 1998), and
echinocandins, which inhibit fungal cell-wall glucan synthesis (Emri
et al., 2013), both show promise as antifungal agents, but few specific
candidates for further trials have emerged (Ostrosky-Zeichner et al.,
2010). Considering the current shortage of new drug candidates in the
antifungal pipeline, the discovery and development of novel fungal-
specific compounds need to be given a high priority. One approach
to achieve this is to apply rational drug-design techniques towards
fungal-specific aspects of otherwise conserved metabolic pathways.
The purine-metabolic pathway has for over half a century served as
a source of targets for therapeutic compounds, including antitumour
drugs, immunosuppressants and antivirals (Elion, 1989). Previous
studies by our group have shown that purine metabolism is a
potential source of antifungal drug targets to combat C. neoformans
infection (Morrow et al., 2010, 2012). We have already characterized a
crucial enzyme in the purine-biosynthesis pathway in this organism,
inosine monophosphate dehydrogenase (IMPDH). IMPDH is the
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first committed step in de novo GTP biosynthesis, catalyzing the
conversion of inosine monophosphate (IMP) to xanthosine mono-
phosphate (XMP). Loss of IMPDH activity, and consequently de
novo GTP biosynthesis, results in death of the pathogen, suggesting
that this pathway may be a viable antifungal target (Morrow et al.,
2012). To further probe this pathway for targets, we have investigated
other purine-biosynthetic enzymes.
Just as IMPDH catalyzes the first step in GTP biosynthesis from
IMP, the first step in the conversion of IMP to ATP is governed by
the enzyme adenylosuccinate synthetase (AdSS). AdSS catalyzes the
formation of adenylosuccinate (S-AMP) from IMP and aspartate.
This GTP- and Mg2+-dependent reaction proceeds via two steps:
firstly, the -phosphate from GTP is transferred to the 6-oxygen of
IMP, forming the intermediate 6-phosphoryl IMP (6-PIMP); secondly,
the 6-phosphoryl group is displaced by the -amino group of aspar-
tate to form adenylosuccinate (Lieberman, 1956; Fig. 1). Structural
studies in Escherichia coli and other organisms have shown that the
enzyme forms a dimer, with each subunit contributing an arginine
residue to the active site of the other molecule (Poland et al., 1993;
Silva et al., 1995; Moe et al., 1996; Eaazhisai et al., 2004). In the
absence of its substrate, the active site of AdSS is disordered;
however, upon ligand binding the substrate-binding pocket and dimer
formation are stabilized (Wang et al., 1995; Hou et al., 2002).
With the exception of mature red blood cells, AdSS is an essential
enzyme in all organisms studied so far and most cell types (Honzatko
& Fromm, 1999; Hou et al., 2002). An alternative route of ATP
biosynthesis is the conversion of adenine salvaged from the envir-
onment to adenosine monophosphate (AMP). This reaction is
governed by the enzyme adenine phosphoribosyl transferase (APRT),
which has been characterized in several organisms, including the
fungus Saccharomyces cerevisiae (Alfonzo et al., 1997). C. neoformans
carries a predicted APRT-encoding gene (strain H99; CNAG_02858,
Broad Institute of MIT and Harvard; http://www.broadinstitute.org/
annotation/genome/cryptococcus_neoformans/MultiHome.html).
AdSS has been purified and characterized from several sources.
AdSS from E. coli is arguably the best characterized (Silva et al., 1995;
Poland et al., 1996; Choe et al., 1999) and has 42% identity to the
cryptococcal enzyme. Crystal structures are also available for the
proteins from Homo sapiens (54% identity; PDB entry 2v40; Struc-
tural Genomics Consortium, unpublished work),Mus musculus (54%
identity; Iancu et al., 2001, 2002), the bacteria Yersinia pestis (42%
identity; PDB entry 3hid; R. Zhang, M. Zhou, S. Peterson, W.
Anderson & A. Joachimiak, unpublished work), Campylobacter
jejuni (43% identity; PDB entry 3r7t; Center for Structural Genomics
of Infectious Diseases, unpublished work) and Burkholderia thai-
landensis (40% identity; PDB entry 3ue9; Seattle Structural Geno-
mics Center for Infectious Disease, unpublished work), the plants
Arabidopsis thaliana (55% identity) and Triticum aestivum (53%
identity; Prade et al., 2000), the eukaryotic parasite Plasmodium
falciparum (46% identity; Eaazhisai et al., 2004) and the extremophile
archaeon Pyrococcus horikoshii (33% identity; Wang et al., 2011).
The enzyme has been crystallized in the apo form (Silva et al., 1995;
Iancu et al., 2001) as well as complexed with various combinations of
IMP, GTP, GDP, aspartate, 6-PIMP, Mg2+ and two AdSS inhibitors:
the antitumour aspartate analogue hadacidin (Kaczka et al., 1962;
Tibrewal & Elliott, 2011) and the adenosine 50-monophosphate-
mimicking herbicide hydantocidin (Fonne´-Pfister et al., 1996).
To date, there have been no crystallographic studies of AdSS from
a fungal species. In the hope that comparison of a fungal AdSS
structure with the comprehensive knowledge available from other
species may prove useful in the design of future fungal-specific agents,
here we describe the crystallization and initial analysis of the crystals
of adenylosuccinate synthetase from C. neoformans.
2. Materials and methods
2.1. Cloning
Total RNAwas isolated from C. neoformans var. grubii strain H99
using TRIzol (Invitrogen). Intron-free cDNA was then synthesized
using a Bioline cDNA synthesis kit (Bioline). The AdSS-encoding
gene ADE12 (strain H99; CNAG_02858, Broad Institute of
MIT and Harvard; http://www.broadinstitute.org/annotation/genome/
cryptococcus_neoformans/MultiHome.html) was PCR-amplified,
with unique restriction sites (BamHI and PstI) introduced via the
specifically designed primers UQ2259 (ACGCACGGATCCATGG-
CTCCATCCCCGGAGGGA) and UQ2260 (GAACGTCTGCAG-
TTAGAAGATGATAACGTTCTG). The PCR product was then
cloned into the TOPO pCR2.1 vector (Invitrogen), sequenced and
ligated into BamHI/PstI-cut pQE-30 expression vector (Qiagen),
which introduced an N-terminal 6His tag (MRGSHHHHHHGS).
2.2. Expression and purification
Early failed cloning efforts strongly suggested that the ADE12
pQE construct was toxic in E. coli. The ligation was therefore
transformed into competent BL21(DE3)pLysSE. coli cells (Promega)
expressing the pREP4 repressor plasmid. Transformed cells were
grown in Terrific Broth (TB) medium with 100 mg ml1 ampicillin,
35 mg ml1 kanamycin and 12.5 mg ml1 chloramphenicol. Cultures
were incubated at 310 K until they reached an OD600 of approxi-
mately 1.0, after which they were induced with 1 mM IPTG and
grown at 293 K for 5 h. Cell pellets were harvested and resuspended
in lysis buffer (50 mM HEPES pH 8, 300 mM NaCl, 1 mM DTT,
30 mM imidazole, 1 mM PMSF) and then lysed by sonication. AdSS
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Figure 1
The reaction catalyzed by adenylosuccinate synthetase.
was purified via Ni-immobilized metal-affinity chromatography using
HisTrap Fast Flow columns (GE Healthcare) and eluted over 20
column volumes in a linear gradient of 30–500 mM imidazole. A
single main elution peak was seen. Fractions corresponding to this
peak were combined and further separated on a Superdex 200 size-
exclusion chromatography (SEC) column (GE Healthcare) equili-
brated in SEC buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM
DTT) using an A¨KTApurifier FPLC system (GE Healthcare).
Peak fractions were combined and concentrated to approximately
16 mg ml1 at >99% purity as estimated by Coomassie-stained SDS–
PAGE and snap-frozen for storage at 193 K.
2.3. Crystallization
All crystallization experiments were performed using the hanging-
drop vapour-diffusion method at 293 K. Initial screening for crys-
tallization conditions was performed using the Index and PEG/Ion
(Hampton Research), PACT premier and JCSG (Qiagen), ProPlex
and Morpheus (Molecular Dimensions) and Synergy (Jena Bio-
sciences) commercial screening plates. Plates were set up using a
Mosquito Nanodrop crystallization robot (TTP LabTech), with each
drop consisting of 100 nl protein solution and 100 nl reservoir solu-
tion inverted over 100 ml reservoir solution. A Rock Imager system
(Formulatrix) was used to monitor crystal growth in the drops.
Crystals were found in approximately 200 conditions. The most
promising candidates were chosen for further screening and optimi-
zation. Final diffraction-quality crystals were obtained using a
condition from the PACT screen. Drops consisting of 1 ml protein
solution at 16 mg ml1 and 1 ml reservoir solution (0.1M bis-tris
propane pH 8, 0.2M sodium bromide, 17% polyethylene glycol 3350)
were streak-seeded from AdSS crystals unsuitable for diffraction
after 30 min equilibration over 500 ml reservoir solution. Long
rectangular crystals of approximately 0.5  0.05  0.05 mm formed
after 24–48 h (Fig. 2).
2.4. Data collection and processing
Crystals were mounted on nylon loops and treated with a cryo-
protectant before being flash-cooled in liquid nitrogen. Initial tests
using 20% glycerol in the crystallization solution caused the crystals
to shatter, so 15% ethylene glycol was used as a cryoprotectant. X-ray
diffraction was performed on the MX2 beamline at the Australian
Synchrotron (Clayton, Australia). Reflections were indexed and
integrated using XDS (Kabsch, 2010) and were then scaled using
AIMLESS (Evans & Murshudov, 2013) as implemented within the
CCP4 suite (Winn et al., 2011)
3. Results and discussion
Full-length His-tagged AdSS from C. neoformans was expressed
heterologously in soluble form in E. coli after 5 h induction at 293 K.
Protein appeared as a single band of approximately 46 kDa on
reducing SDS–PAGE, matching the estimated size of His-tagged
AdSS. During SEC, the protein elutes at 220 ml, which, based on
its expected molecular weight and protein calibration standards,
suggests a monomeric state in solution. This is in keeping with the
established model in which AdSS dimerization is dependent on
ligand binding (Kang et al., 1996).
Following the large number of hits obtained from initial sparse-
matrix screening, trends in crystallization conditions were investi-
gated. Many hits occurred in conditions using polyethylene glycol
3350 as a precipitant with various types of salts. After comparing the
morphologies of these hits, a buffer containing polyethylene glycol
3350 and sodium bromide was chosen. Further rounds of optimiza-
tion by varying the pH and the PEG concentration and by the
addition or absence of glycerol led to large diffraction-quality crystals
in 0.1M bis-tris propane pH 8, 0.2M sodium bromide, 17% poly-
ethylene glycol 3350. Protein crystals appeared after 24–48 h at 293 K
(Fig. 2). The resolution of the best-diffracting crystals was 2.2 A˚.
Data-collection and refinement statistics are summarized in Table 1.
The crystals are most likely to contain two molecules in the asym-
metric unit (corresponding to a Matthews coefficient of 2.61 A˚3 Da1;
Matthews, 1968).
Current work is focusing on solving the structure of AdSS by
molecular replacement based on the most similar crystallized
homologue (that from A. thaliana) as well as obtaining data sets for
ligand-bound and inhibitor-bound forms. Analysis of these structures
may reveal differences from the human enzyme that could be
exploited by structure-based inhibitor design to create leads for new
antifungal therapeutics.
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Figure 2
Crystals of adenylosuccinate synthetase from C. neoformans, space group P212121.
Table 1
Data-collection and refinement statistics.
Values in parentheses are for the outer shell.
No. of crystals 1
Diffraction source Australian Synchrotron MX2
X-ray wavelength (A˚) 0.95
Detector ADSC Quantum 315r
Crystal-to-detector distance (mm) 250
Rotation range per image () 1
Total rotation range () 360
Exposure time per image (s) 2
Data-collection temperature (K) 100
Space group P212121
Unit-cell parameters (A˚, ) a = 58.08, b = 101.00, c = 163.80,
 =  =  = 90





Rmeas = Rr.i.m.‡ 0.073 (1.415)
Wilson B factor (A˚2) 41.74











i IiðhklÞ, where Ii(hkl) is the intensity of
an individual measurement of the reflection with Miller indices hkl and hI(hkl)i is the
mean intensity of that reflection. Calculated for I > 3(I). ‡ Rmeas = Rr.i.m. =P
hklfNðhklÞ=½NðhklÞ  1g1=2
P




i IiðhklÞ, where Ii(hkl) is the
intensity of the ith observation of reflection hkl and hI(hkl)i is the weighted average
intensity of all observations i of reflection hkl. N(hkl) is the multiplicity.
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